I also compare Clinuvel to other asx biotech stocks. They are profitable due to a failed strategy of inadequately reinvesting in their pipeline, possibly due to the board falling asleep during a dr wright presentation. However, Clinuvel are hopeless and embarrassing with respect to their communication, treatment of shareholders and ability to execute. Wolgen is extremely well paid ( tax free in Monaco) and speaks in riddles and unable to answer a direct question but allegedly delivers market sensitive information selectively during private discussions.
good luck with your investment
Ann: Syd Capital Markets Briefing Presentation, page-60
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.84 |
Change
0.260(1.78%) |
Mkt cap ! $743.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $1.349M | 91.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 644 | $14.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.85 | 3489 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |